.Pharmacolibrary.Drugs.ATC.L.L01EL03 .Pharmacolibrary.Drugs.ATC.L.L01EL03| name: | Zanubrutinib | |
| ATC code: | L01EL03 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 160 | mg |
| volume of distribution: | 128 | L |
| clearance: | 15.7 | L/h |
| other parameters in model implementation | ||
Zanubrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies such as mantle cell lymphoma, Waldenström's macroglobulinemia, and chronic lymphocytic leukemia. It has received FDA approval for certain hematological cancers.
Pharmacokinetic parameters reported for patients with B-cell malignancies following oral administration of zanubrutinib at a dose of 160 mg, twice daily. Data primarily from adult patients.
Mu, S, et al., & Sahasranaman, S (2020). Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer chemotherapy and pharmacology 85(2) 391–399. DOI:10.1007/s00280-019-04015-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/31875923